Isabella Montagna’s research while affiliated with Chiesi Farmaceutici S.p.A. and other places

... The model was trained based on spirometry measurements from the National Health and Nutritional Examination Survey (NHANES 2011-2012) 12 and validated in clinical trial settings. 14 The spirometry interpretation component is a decision support software focusing on the diagnostic interpretation of spirometry sessions. It provides support in pattern interpretation according to international interpretation guidelines (ie, normal, obstructive and/or restrictive) 15 and a disease probability. ...

Reference:

Comparing performance of primary care clinicians in the interpretation of SPIROmetry with or without Artificial Intelligence Decision support software (SPIRO-AID): a protocol for a randomised controlled trial

... Accuracy was highest in asthma (90%, specificity 84%) and lowest in COPD (43%) due to low specificity (52%) and PPV (25%). 19 Robertson et al. reported collaboration between pulmonologists and explainable AI improves interpretation accuracy, requiring appropriate training and oversight 20 Our study confirms that ChatGPT spirometry interpretation aligns closely with respiratory physician assessments, particularly for normal, restrictive, and mixed patterns. Discrepancies in the classification of spirometry, AI demonstrated high diagnostic accuracy and consistency. ...

Reference:

Accuracy Of Spirometric Interpretation by Artificial Intelligence-Based Software in Comparison with Spirometric Interpretation by A Qualified Respiratory Physician in A Tertiary Care Center in Chengalpattu District

... The Artiq.QC software evaluates the quality of the data by checking the numerical quality criteria, as well as the visual shape of the curve with its deep-learning artificial intelligence. 26 Doing so mimics the human visual evaluation of the curve, typically done by human over-readers. It can detect artefacts defined by the ATS/ERS standards and evaluate the impact of these artefacts on the acceptability and/or usability of the data. ...

Reference:

Chronic respiratory disease observatory for Africa (CHEST-Africa): study protocol for the prevalence, determinants and economic impacts of asthma and COPD in Africa

... Recently, it has been demonstrated in a retrospective study that machine learning software may be helpful in clinical trials to ensure the quality consistency of spirometry evaluation promptly in comparison to human over-readers [13]. In a very recent study [14], spirometry PDF files collected during hospital examinations A c c e p t e d M a n u s c r i p t were labeled according to ATS/ERS 2019 criteria, and a deep learning model was constructed to determine acceptability, usability, and quality rating for FEV1 and FVC. ...

Reference:

Deep learning algorithm for visual quality assessment of the spirograms

... p = 0.037). 103,104 In conclusion, a fixed combination of three drugs in a single inhaler can improve long-term adherence to the therapy, reducing the risk of exacerbations and hospital resources utilization. The twice a day administration may provide a better coverage at night, particularly in highly symptomatic COPD patients. ...

Reference:

Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution

... 2,16,17 Despite these available therapeutic options, and challenges association with smoking cessation, it is estimated that 30% to 60% of patients continue to experience moderate to severe exacerbations while receiving dual or triple inhaled therapy, highlighting an unmet medical need for more effective treatment options for the management of COPD exacerbations. [18][19][20][21][22][23] Several monoclonal antibodies targeting different inflammatory pathways are currently under development, and one has been recently approved, aimed at decreasing exacerbation risk and improving symptoms in people with COPD who continue to experience exacerbations while on inhaled dual or triple therapy. [24][25][26][27] However, the patients enrolled in clinical trials may differ from the heterogenous real-world population 28 and little is known about the characteristics and clinical outcomes of this COPD population in routine clinical practice. ...

Reference:

Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015–2019)

... Studies have specifically examined the cardiovascular safety profile of fixed-dose combinations incorporating glycopyrronium and formoterol delivered via inhalers. These investigations have indicated that GFF therapy, administered through a metered dose inhaler utilizing Co-Suspension™ delivery technology, exhibits a favorable cardiovascular safety profile [27,28]. Additionally, the cardiovascular safety profiles of alternative combination therapies, such as QVA149 and budesonide/glycopyrrolate/formoterol fumarate, have also been evaluated, underscoring the importance of assessing cardiovascular effects when considering treatment options for respiratory conditions [29,30]. ...

Reference:

Comparing Glycopyrronium/Formoterol Combination Therapy With Monotherapy in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD): A Narrative Review

... From these, we identified 105 as potentially relevant. A full-text analysis led to the removal of 90, leaving 15 records (seven abstracts/posters) belonging to six studies for inclusion ( Fig. 1) [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. Detailed reasons for exclusion are outlined in Additional file 1: Table S3. ...

Reference:

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review

... ICSs/LAMAs/LABAs had significant benefits for the reduction of acute exacerbations [9,[12][13][14][15], symptoms [15,16], and rescue medication use [17], and the improvement of lung function [13,15,16] compared with ICSs/ LABAs or LAMAs/LABAs in randomized controlled trials (RCTs). Furthermore, we previously showed that triple therapy reduced all-cause mortality compared with other dual or single treatments [18]. ...

Reference:

Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis

... 2,16,17 Despite these available therapeutic options, and challenges association with smoking cessation, it is estimated that 30% to 60% of patients continue to experience moderate to severe exacerbations while receiving dual or triple inhaled therapy, highlighting an unmet medical need for more effective treatment options for the management of COPD exacerbations. [18][19][20][21][22][23] Several monoclonal antibodies targeting different inflammatory pathways are currently under development, and one has been recently approved, aimed at decreasing exacerbation risk and improving symptoms in people with COPD who continue to experience exacerbations while on inhaled dual or triple therapy. [24][25][26][27] However, the patients enrolled in clinical trials may differ from the heterogenous real-world population 28 and little is known about the characteristics and clinical outcomes of this COPD population in routine clinical practice. ...

Reference:

Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015–2019)